Skip to content

Author

Naijipu Abuduaini

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Clinical trial Open access Aug 2026

A multicohort, biomarker-driven phase 2 trial of personalized total neoadjuvant therapy with targeted agents for high-risk rectal cancer (The TRAINER study)

This multicohort, single-center, phase II trial explored the efficacy and safety of a biomarker-driven total neoadjuvant therapy (TNT) regimen in high-risk locally advanced rectal cancer (LARC) patients. The regimen included induction chemotherapy (4 cycles of mFOLFOX6) with targeted agents (bevacizumab for cohort B an...

T. Ma, Jingyi Liu, Sen Zhang et al. · 0 citations
Open access Jul 2026

DHODH is a synthetic lethal target in PIK3CA-mutant colorectal cancer.

It is demonstrated that the metabolic regulation of protein stability represents a critical mechanism underlying oncogene-specific dependencies in CRC.

Jun Liang, Xi Liu, Ziyun Ni et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.